Search results for "Remission Induction"

showing 10 items of 141 documents

Stone-Free Rate after Treating Kidney Stones Exceeding 10 mm via Flexible Ureteroscopy: Can Endoscopic Assessment Replace Low-Dose Computed Tomograph…

2019

<b><i>Introduction:</i></b> It is unclear whether endoscopic assessment of the stone-free rate after flexible ureteroscopy (fURS) is as effective as assessment with low-dose computed tomography (CT) scan. <b><i>Methods:</i></b> Prospective documentation of patients with kidney stones > 10 mm diameter from 2 different centers (Freiburg, Regensburg), who underwent fURS and were declared to be endoscopically completely stone-free. Low-dose CT control performed 4–8 weeks postoperatively. <b><i>Results/Conclusion:</i></b> Thirty-eight patients were treated between October 2015 and August 2016 (12 F, 26 M). Average a…

AdultMaleUrologyStone freemedicine.medical_treatment030232 urology & nephrologyComputed tomographyFlexible ureteroscopyLithotripsyRadiation Dosage03 medical and health sciencesKidney CalculiYoung Adult0302 clinical medicinemedicineUreteroscopyHumansUreteroscopyProspective StudiesAged2. Zero hungerAged 80 and overmedicine.diagnostic_testbusiness.industryLow doseRemission InductionEquipment DesignMiddle Agedmedicine.disease3. Good healthTreatment Outcome030220 oncology & carcinogenesisUreteroscopesKidney stonesFemaleStone removalbusinessNuclear medicineTomography X-Ray ComputedUrologia internationalis
researchProduct

Adalimumab in steroid-dependent Crohn's disease patients: prognostic factors for clinical benefit.

2012

Background: Corticosteroids are effective in the treatment of Crohn's disease but some patients relapse during tapering or after discontinuation. We report data on efficacy and prognostic factors of response of adalimumab in steroid-dependent patients. Methods: In all, 110 steroid-dependent patients were treated with adalimumab (80/40 or 160/80 mg every other week followed by 40 mg every other week). Clinical remission was defined as steroid discontinuation without symptomatic recurrence and clinical response as the reduction or maintenance of the initial Crohn's Disease Activity Index (CDAI) value reducing steroid dosage but without its discontinuation at week 6 and at the end of follow-up…

AdultMalemedicine.medical_specialtyAdolescentAnti-Inflammatory AgentsAntibodies Monoclonal HumanizedInflammatory bowel diseaseYoung AdultCrohn DiseaseInternal medicinemedicineAdalimumabSecondary PreventionImmunology and AllergyHumansProspective StudiesYoung adultProspective cohort studyGlucocorticoidsAgedUnivariate analysisCrohn's diseasebusiness.industryRemission InductionGastroenterologyAdalimumabMiddle Agedmedicine.diseasePrognosisSurgeryDiscontinuationRegimenFemalebusinessmedicine.drugFollow-Up StudiesInflammatory bowel diseases
researchProduct

Efficacy of Short-term Treatment of Internet and Computer Game Addiction

2019

Importance Internet and computer game addiction represent a growing mental health concern, acknowledged by the World Health Organization. Objective To determine whether manualized cognitive behavioral therapy (CBT), using short-term treatment for internet and computer game addiction (STICA), is efficient in individuals experiencing internet and computer game addiction. Design, Setting, and Participants A multicenter randomized clinical trial was conducted in 4 outpatient clinics in Germany and Austria from January 24, 2012, to June 14, 2017, including follow-ups. Blinded measurements were conducted. A consecutive sample of 143 men was randomized to the treatment group (STICA; n = 72) or wai…

AdultMalemedicine.medical_specialtyAdolescentmedia_common.quotation_subjectlaw.inventionYoung Adult03 medical and health sciences0302 clinical medicineRandomized controlled triallawOutcome Assessment Health CareComputer addictionHumansOutpatient clinicMedicinemedia_commonCognitive Behavioral Therapybusiness.industryAddictionRemission Inductionmedicine.disease030227 psychiatryComputer gamePsychiatry and Mental healthInternet addiction disorderVideo GamesPhysical therapyPsychotherapy BriefbusinessAddictive behaviorPsychosocialInternet Addiction Disorder030217 neurology & neurosurgeryFollow-Up StudiesJAMA Psychiatry
researchProduct

The Neutrophil-to-Lymphocyte ratio as a marker of recovery status in patients with severe dental infection.

2017

Background The aim of the study was to assess the value of pretreatment neutrophil/lymphocyte (N/L) ratio and mean platelet volume (MPV) and the correlation between these markers with progression in patients with severe odontogenic infection. Material and Methods A cohort of 100 patients with severe odontogenic infection were divided into 2 groups according to their length of hospital stay. The N/L ratio and MPV was measured in all patients. The correlation in all patients between preoperative fever, preoperative antibiotic doses, postoperative antibiotic doses, total antibiotic doses and hospital stay with N/L ratio and MPV were analyzed. The Youden index was used to identify the optimal c…

AdultMalemedicine.medical_specialtyAdolescentmedicine.drug_classNeutrophilsLymphocyteAntibioticsInfectionsGastroenterologySeverity of Illness Index03 medical and health sciencesLeukocyte CountYoung Adult0302 clinical medicineInternal medicineSeverity of illnessmedicineHumansLymphocytesNeutrophil to lymphocyte ratioMean platelet volumeChildGeneral DentistryRetrospective StudiesOdontogenic infectionOral Medicine and Pathologybusiness.industryResearchRemission InductionRetrospective cohort study030206 dentistry:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseSurgeryAnti-Bacterial Agentsmedicine.anatomical_structureOtorhinolaryngologyTooth Diseases030220 oncology & carcinogenesisCohortUNESCO::CIENCIAS MÉDICASDisease ProgressionSurgeryFemalebusinessMean Platelet VolumeBiomarkersMedicina oral, patologia oral y cirugia bucal
researchProduct

Anti–Interleukin-12 Antibody for Active Crohn's Disease

2004

Crohn's disease is associated with excess cytokine activity mediated by type 1 helper T (Th1) cells. Interleukin-12 is a key cytokine that initiates Th1-mediated inflammatory responses.This double-blind trial evaluated the safety and efficacy of a human monoclonal antibody against interleukin-12 (anti-interleukin-12) in 79 patients with active Crohn's disease. Patients were randomly assigned to receive seven weekly subcutaneous injections of 1 mg or 3 mg of anti-interleukin-12 per kilogram of body weight or placebo, with either a four-week interval between the first and second injection (Cohort 1) or no interruption between the two injections (Cohort 2). Safety was the primary end point, an…

AdultMalemedicine.medical_specialtyColonmedicine.medical_treatmentPlaceboGastroenterologychemistry.chemical_compoundCrohn DiseaseDouble-Blind MethodInternal medicinemedicineClinical endpointBriakinumabHumansAgedAged 80 and overCrohn's diseasebiologybusiness.industryRemission InductionAntibodies MonoclonalGeneral MedicineMiddle Agedmedicine.diseaseInterleukin-12digestive system diseasesCytokinechemistryImmunologyCohortLeukocytes MononuclearInterleukin 12biology.proteinCytokinesFemaleAntibodybusinessNew England Journal of Medicine
researchProduct

The Addition of an Immunosuppressant After Loss of Response to Anti-TNFα Monotherapy in Inflammatory Bowel Disease: A 2-Year Study

2018

Background The addition of an immunosuppressant (IM) after loss of response to anti-TNFα monotherapy is an emerging strategy of therapeutic optimization in patients with inflammatory bowel disease (IBD). However, few clinical data have been reported to date. We aimed to evaluate the efficacy and safety of this selective combination therapy in patients with IBD. Methods All consecutive patients with loss of response to anti-TNFα monotherapy despite an intensive dose optimization who added an IM from October 2014 to October 2016 were entered into a prospective database. Results Among 630 patients treated with anti-TNFα agents during the study period, 46 (7.3%) added an IM. A total of 31 patie…

AdultMalemedicine.medical_specialtyDatabases FactualCombination therapyGastroenterologyInflammatory bowel diseaseDrug Administration Schedule03 medical and health sciences0302 clinical medicineInternal medicinemedicineAdalimumabHumansImmunology and AllergyProspective StudiesAdverse effectbiologyTumor Necrosis Factor-alphabusiness.industryRemission InductionC-reactive proteinAdalimumabGastroenterologyAntibodies MonoclonalMiddle AgedInflammatory Bowel Diseasesmedicine.diseaseInfliximabGolimumabInfliximabDiscontinuationC-Reactive ProteinTreatment Outcome030220 oncology & carcinogenesisbiology.proteinDrug Therapy CombinationFemale030211 gastroenterology & hepatologybusinessImmunosuppressive Agentsmedicine.drugInflammatory Bowel Diseases
researchProduct

Infliximab in the treatment of Crohn's disease: Predictors of response in an Italian multicentric open study

2005

Abstract Background. Almost 20% of patients with active Crohn's disease are refractory to conventional therapy. Infliximab is a treatment of proven efficacy in this group of patients and it is not clear which variables predict a good response. Aims. To evaluate the role of infliximab looking at the predictors of response in a large series of patients with Crohn's disease. Patients and methods. Five hundred and seventy-three patients with luminal refractory Crohn's disease (Crohn's Disease Activity Index (CDAI) > 220–400) (312 patients) or with fistulising disease (190 patients) or both of them (71 patients) were treated with a dose of 5 mg/kg in 12 Italian referral centres. The primary endp…

AdultMalemedicine.medical_specialtyFistulaPredictors of responseAge at diagnosisDiseaseGastroenterologyAntibodiesDose-Response RelationshipCrohn DiseaseGastrointestinal AgentsRefractoryInternal medicineMonoclonalmedicineHumansinfliximab.crohn's disease.Settore MED/12 - GastroenterologiaCrohn's diseaseDose-Response Relationship DrugHepatologybusiness.industryRemission InductionSmokingGastroenterologyAntibodies Monoclonalmedicine.diseaseCrohn's Disease Activity IndexInfliximabInfliximabSurgeryOpen studyCrohn's diseaseCrohn's disease; Infliximab; Predictors of response; Adult; Antibodies Monoclonal; Crohn Disease; Dose-Response Relationship Drug; Female; Fistula; Gastrointestinal Agents; Humans; Infliximab; Italy; Male; Multivariate Analysis; Remission Induction; SmokingItalyConcomitantMultivariate AnalysisFemaleCrohn's disease; Infliximab; Predictors of responseDrugbusinessmedicine.drugDigestive and Liver Disease
researchProduct

Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leu…

2015

Outcome of patients with primary refractory acute myeloid leukemia remains unsatisfactory. We conducted a prospective phase II clinical trial with gemtuzumab ozogamicin (3 mg/m(2) intravenously on day 1), all-trans retinoic acid (45 mg/m(2) orally on days 4-6 and 15 mg/m(2) orally on days 7-28), high-dose cytarabine (3 g/m(2)/12 h intravenously on days 1-3) and mitoxantrone (12 mg/m(2) intravenously on days 2-3) in 93 patients aged 18-60 years refractory to one cycle of induction therapy. Primary end point of the study was response to therapy; secondary end points included evaluation of toxicities, in particular, rate of sinusoidal obstruction syndrome after allogeneic hematopoietic cell tr…

AdultMalemedicine.medical_specialtyGemtuzumab ozogamicinmedicine.medical_treatmentSalvage therapyTretinoinComorbidityKaplan-Meier EstimateAntibodies Monoclonal HumanizedGastroenterology03 medical and health sciencesYoung Adult0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansSalvage TherapyMitoxantroneChemotherapybusiness.industryRemission InductionCytarabineHematopoietic Stem Cell TransplantationMyeloid leukemiaHematologyArticlesMiddle Agedmedicine.diseaseGemtuzumab3. Good healthSurgeryTransplantationConsolidation ChemotherapyLeukemiaLeukemia Myeloid AcuteAminoglycosidesTreatment Outcome030220 oncology & carcinogenesisCytarabineFemaleMitoxantronebusiness030215 immunologymedicine.drugHaematologica
researchProduct

Peripheral blood stem cell (PBSC) mobilization with chemotherapy followed by sequential IL-3 and G-CSF administration in extensively pretreated patie…

1998

Extensive pretreatment has been identified as a significant risk factor for failure of sufficient PBSC mobilization. From published data and our own experience we defined pretreatment variables which render patients at risk for not collecting at least 2.5 x 10(6) CD34-positive cells per kg bodyweight (BW). These variables were previous unsuccessful PBSC mobilization trial, previous large field radiotherapy, four or more cycles of myelosuppressive chemotherapy regimens, and combinations of extended field radiotherapy plus chemotherapy. Based on these inclusion criteria we treated 19 patients with disease-specific conventional-dose chemotherapy followed by sequential subcutaneous administrati…

AdultMalemedicine.medical_specialtyNeutropeniaFevermedicine.medical_treatmentPainSalvage therapyGastroenterologyTesticular NeoplasmsRisk FactorsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsGranulocyte Colony-Stimulating FactormedicineHumansMultiple myelomaTesticular cancerSalvage TherapyTransplantationMyelosuppressive ChemotherapyChemotherapybusiness.industryRemission InductionHematopoietic Stem Cell TransplantationDrug SynergismHematologyMiddle Agedmedicine.diseaseCombined Modality TherapyHematopoietic Stem Cell MobilizationBlood Cell CountSeminomaSurgeryGranulocyte colony-stimulating factorLymphomaRegimenHematologic NeoplasmsFemaleInterleukin-3GerminomabusinessBone Marrow Transplantation
researchProduct

Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study.

2000

Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) of unknown etiology frequently requiring long-term therapy for control of symptoms and prevention of relapse. Azathioprine (AZA) has been shown to be effective and safe in the treatment of chronic active UC. However, the alternatives to treatment with AZA are limited. Our aim was to compare the efficacy and safety of treatment with mycophenolate mofetil (MMF)/prednisolone versus standard immunosuppressive treatment with azathioprine (AZA)/prednisolone in patients with chronic active UC.The study was designed as an open comparison of MMF versus AZA. Twenty-four patients with active UC (Rachmilewitz scoreor =6 points) were randoml…

AdultMalemedicine.medical_specialtyRandomizationPrednisoloneAzathioprinePilot ProjectsMycophenolateGastroenterologyMycophenolic acidInternal medicineAzathioprineMedicineHumansColitisGlucocorticoidsAgedHepatologybusiness.industryChronic ActiveRemission InductionGastroenterologyMiddle AgedMycophenolic Acidmedicine.diseaseUlcerative colitisSurgeryChronic DiseasePrednisoloneColitis UlcerativeDrug Therapy CombinationFemalebusinessImmunosuppressive Agentsmedicine.drugThe American journal of gastroenterology
researchProduct